The so-called fundamentals, frankly, don't really matter for Entest BioMedical Inc. (OTCMKTS:ENTB) or Gevo, Inc. (NASDAQ:GEVO). Oh, both GEVO and ENTB are generating sales, but both are consistently taking losses. That's ok though, as for both companies right now, profits aren't really the point - it's the pipeline that matters.
Then again, though both Gevo, Inc. and Entest BioMedical Inc. are on the same proverbial expectations-boat doesn't mean neither are trade-worthy. As a matter of fact, both are quite trade-worthy explicitly because they are nothing more than trading instruments, being pushed around by speculation and psychology, which is - amazingly enough - sometimes easier to handicap than actual "value". Thing is, though both ENTB and GEVO are dropping big hints as to the budding direction of their bigger undertow, these two stocks are most definitely not pointed in the same direction.
Top New Companies To Invest In Right Now: Biota Pharmaceuticals Inc (BOTA)
Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.
The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.
Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.
PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.
Advisors' Opinion:- [By gurujx]
Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42
The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.
Top 10 Medical Companies To Invest In 2014: Cyberonics Inc (CYBX)
Cyberonics, Inc. (Cyberonics), incorporated in 1987, is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.
The United States Food and Drug Administration (FDA) approved the Company's VNS Therapy System in July 1997 for use as an adjunctive therapy in epilepsy patients over 12 years of age for reducing the frequency of partial onset seizures that are refractory or resistant to antiepileptic drugs. Regulatory bodies in Canada, the European Economic Area, certain countries in Eastern Europe, Russia, South America, Africa, Australia and certain countries in Asia, including Japan, China and Taiwan, have approved the VNS Therapy System for the treatment of epilepsy, many without age restrictions or seizure-type limitations. In July 2005, the FDA approved the Company's VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a depressive episode and have not had an adequate response to four or more adequate anti-depressant treatments. Regulatory bodies in the European Economic Area, Canada and Israel have approv! ed the Company's VNS Therapy System for the treatment of chronic or recurrent depression in patients who are in a treatment-resistant or treatment-intolerant depressive episode without age restrictions.
In February 2011, the Company announced FDA approval of its fifth generation generator, the AspireHC generator. In August 2011, the Company announced that the Company discovered a hardware-related design issue with the AspireHC Model 105 and AspireSR (Seizure Response) Model 106 generators. In December 2011, the FDA approved the Company's re-designed AspireHC generator, and the Company resumed its limited commercial release of the generator in the United States.
Pulse Generator
The pulse generator is an implantable, programmable signal generator designed to be coupled with the bipolar lead to deliver mild electrical pulses to the vagus nerve. The pulse generator is a battery-powered device. Before or upon depletion of the battery, the pulse generator may be removed and a new generator implanted in a short, outpatient procedure. The Model 102 (Pulse), Model 102R (Pulse Duo ), Model 103 (Demipulse), Model 104 (Demipulse Duo) and Model 105 (AspireHC), are the VNS Therapy pulse generators the Company offers and are similar in design and manufactures to a cardiac pacemaker.
Bipolar Lead
The bipolar lead conducts the electrical signal from the pulse generator to the vagus nerve. The lead incorporates electrodes, which are self-sizing, minimizing mechanical trauma to the nerve. The lead's two electrodes and anchor tether wrap around the vagus nerve, and the connector end is tunneled subcutaneously to the upper chest area, where it attaches to the pulse generator. The Company offers three lead models in the United States. The leads are available in two inner spiral diameter sizes to ensure optimal electrode placement on different-sized nerves.
Programming Wand and Software
The Company's programming wand and software are us! ed to int! errogate the implanted pulse generator and to transmit programming information from a handheld computer to the pulse generator via an inductive coupling. Programming capabilities include modification of the pulse generator's programmable parameters (pulse width, amplitude and frequency and stimulation ON and OFF intervals) and storage and retrieval of telemetry data.
Tunneling Tool
The tunneling tool is a single use, sterile, disposable surgical tool designed to be used during surgical placement of the bipolar lead. The tool is used for subcutaneous tunneling of the lead between the nerve site in the neck and the pulse generator site in the upper chest area.
Accessory Pack
The accessory pack includes two resistor assemblies used to test the function of the device prior to implantation, the bipolar lead tie-downs and one hex screwdriver. The patient kit includes two magnets, one watch-style and one pager-style.
The Company competes with Medtronic, Inc., NeuroSigma Inc. and CerboMed GmbH.
Advisors' Opinion:- [By Benjamin Shepherd]
The rise of public health services, improvements in sanitation and access to clean drinking water have led to a huge improvement in human life expectancy, which has jumped from only about 30 years five centuries ago to more than 75 years in most industrialized countries today.
Advances in medical science have also played a major role, such as the development of antibiotics to treat once deadly infections, surgical interventions to correct once fatal injuries and medications to treat chronic conditions.
We have yet to reach the limit of human ingenuity and today the trend is towards harnessing technology to break the reliance on long-term medication usage to treat chronic conditions. One area where huge strides are being made in that direction is the treatment of epilepsy.
Epilepsy is the fourth most common neurological disease in the world, affecting more than 9 million people in developed countries alone, and epileptics have a mortality rate more than 25 times higher than the general population. The costs associated with dealing with the disease run in excess of $13.5 billion in the US alone.
The disease is typically treated using a drug regime that includes several pills a day, including anti-convulsants and sedatives which can have unpleasant side effects. Drug therapy is typically successful in controlling seizures in about 70 percent of patients, but about a third of those who don�� respond to medication find themselves undergoing surgery to essentially remove the area of the brain triggering the seizures.
Cyberonics (NSDQ: CYBX) is making headway into an alternative treatment for the disease, called vagus nerve stimulation (VNS) therapy, which can reduce the number or even eliminate the need for the drugs epileptics depend upon and requires only minor surgery.
During an outpatient procedure conducted under general anesthesia, two small incisions are made, one in the upper chest area and the other in the neck. At t - [By James E. Brumley]
Investors who were hoping things would work out for epilepsy treatment company Cyberonics, Inc. (NASDAQ:CYBX) can cross CYBX off their list of epilepsy-oriented stocks to buy, as they did with Acorda Therapeutics Inc. (NASDAQ:ACOR) about a month ago. ACOR saw its epilepsy drug Plumiaz rejected by the FDA in early May, while CYBX announced this morning that the coming fiscal year's (beginning in April) revenue would be weaker than first expected as sales of its epileptic control implant device didn't look quite as promising as hoped.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Cyberonics (Nasdaq: CYBX ) , whose recent revenue and earnings are plotted below. - [By Roberto Pedone]
Another potential earnings short-squeeze candidate is implantable medical devices player Cyberonics (CYBX), which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Cyberonics to report revenue of $74.05 million on earnings of 55 cents per share.
Read More: 5 Breakout Stocks Under $10 Set to Soar
The current short interest as a percentage of the float for Cyberonics is rather high at 11.6%. That means that out of the 21.65 million shares in the tradable float, 2.52 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 4%, or by about 97,000 shares. If the bears get caught pressing their bets into a strong quarter, then shares of CYBX could easily rip sharply higher post-earnings as the shorts rush to cover some of their trades.
From a technical perspective, CYBX is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock recently formed a double bottom chart pattern at $55.75 to $56.56 a share. Following that bottom, shares of CYBX have started to trend back above its 50-day moving average of $59.83 a share and it's quickly moving within range of triggering a near-term breakout trade above some key overhead resistance levels.
If you're bullish on CYBX, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $63.65 to $64.08 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 228,522 shares. If that breakout materializes post-earnings, then CYBX will set up to re-test or possibly take out its next major overhead resistance levels at $67.12 to $69.18 a share, or even $72 to its 52-week high at $73.52 a share.
I would avoid CYBX or look for short-biased trades if after earnin
Top 10 Medical Companies To Invest In 2014: BIND Therapeutics Inc (BIND)
BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).
Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.
Advisors' Opinion:- [By Garrett Cook]
BIND Therapeutics (NASDAQ: BIND) was down, falling 10.56 percent to $11.52 after the company reported the closing of collaboration deal with Amgen (NASDAQ: AMGN).
- [By Anna Prior]
Bind Therapeutics sa(BIND)id a collaboration with Amgen Inc.(AMGN) has been ended after both companies agreed not to pursue an option to jointly develop a molecularly targeted cancer therapy. Bind Therapeutics shares fell 11% to $11.50 premarket.
- [By John Udovich]
Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.
Top 10 Medical Companies To Invest In 2014: Tauriga Sciences Inc (TAUG)
Tauriga Sciences, Inc., formerly Immunovative, Inc., incorporated on April 18, 2001, is a development-stage company. The Company along with Constellation Diagnostics, Inc. (Constellation) focuses on establishing a joint venture partnership to develop and commercialize a imaging-based diagnostic technology for use in predictive and preventative oncology.
The Company has rights to commercialize AlloStim and AlloVax. As of March 31, 2013 the Company did not have any revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap health care or personal care stocks Axxess Pharma Inc (OTCMKTS: AXXE), Radiant Creations Group Inc (OTCBB: RCGP) and Tauriga Sciences Inc (OTCMKTS: TAUG) have recently been attracting attention in various investment newsletters or in investor alerts. Some of the attention may have to do with paid promotions that two of these small caps have been the subject of. So how healthy are these three small cap health care or personal care orientated stocks? Here is a checkup:
- [By Peter Graham]
Small cap marijuana stocks IMD Companies Inc (OTCMKTS: ICBU), Tauriga Sciences Inc (OTCMKTS: TAUG), ML Capital Group Inc (OTCBB: MLCG) and Lexaria Corp (OTCMKTS: LXRP) are aiming to give investors a high with their latest news. However, only one of these small cap marijuana stocks appears to be the subject of minor paid promotion or investor relations type of activities. So will investors and traders alike get a high off of these small caps? Here is a quick reality check:
Top 10 Medical Companies To Invest In 2014: Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.
The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.
Advisors' Opinion:- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.
- [By Ben Levisohn]
Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.
BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.
- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.
Top 10 Medical Companies To Invest In 2014: Cerus Corporation(CERS)
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company?s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. Cerus Corporation has collaboration agreements with Baxter International, Inc.; and BioOne Corporation, as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.
Advisors' Opinion:- [By Seth Jayson]
Cerus (Nasdaq: CERS ) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cerus's revenues will expand 15.0% and EPS will remain in the red.
Top 10 Medical Companies To Invest In 2014: Johnson & Johnson(JNJ)
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.
Advisors' Opinion:- [By Mike Deane]
Before the opening bell on Tuesday, Johnson & Johnson (JNJ) announced its fourth quarter and full year earnings results, posting higher sales for both time frames compared to last year’s Q4 and full year figures.
JNJ Earnings in Brief
Johnson & Johnson’s worldwide quarterly sales came in at $18.4 billion, up 6.3% from last year’s Q4 sales of $17.6 billion; however, due to negative currency impacts, the sales gain comes in at 4.5%. Excluding special items, JNJ’s net earnings for the quarter came in at $3.6 billion, or $1.24 per share, increasing from $3.4 billion, or $1.19 per share, in last year’s Q4. JNJ beat analysts’ estimates of $1.20 EPS on revenues of $17.95 billion. The company announced full year sales of $71.3 billion and EPS of $4.81, marking increases from last year’s full year results. Looking ahead to full year 2014, JNJ gave earnings estimates in the range of $5.75 to $5.85, which is on the low end of what analysts are looking for.CEO Commentary
Alex Gorsky, JNJ’s CEO and chairman, had the following to say about the company’s earnings report:�”Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business.� We also advanced our longer term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence. I am proud of our exceptional Johnson & Johnson colleagues for their commitment to leading with purpose and advancing health and well-being for patients and consumers around the world.”
No Mention of Dividend
JNJ did not mention any dividend changes in its earnings report. The company most recently announced a dividend increase in April 2013, when it raised its dividend
No comments:
Post a Comment